OPRX OptimizeRx Corp

OptimizeRx Continues Coronavirus Conversation Series with Leaders of NextGen and Illumina

OptimizeRx Continues Coronavirus Conversation Series with Leaders of NextGen and Illumina

Session to Focus on Frontline Healthcare Provider Communication During the COVID-19 Pandemic

ROCHESTER, Mich., March 25, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, will continue its webinar series on navigating the coronavirus (COVID-19) this week with leaders from and .

The ongoing conversations are part of OptimizeRx’s initiative to facilitate industry collaboration to help stop the spread of the virus. More than 400 members of the healthcare community have participated in the webinars which began last week.

William Febbo, CEO of OptimizeRx, will lead the panel. He will be joined by Rusty Frantz, president and CEO of NextGen, and Phil Febbo, chief medical officer and SVP of Illumina. The panel will be moderated by Rebecca Love, VP of customer strategy and engagement for OptimizeRx.

Topic: Learning Together: Frontline HCP Communication During COVID-19

This webinar is designed to be a resource for HCPs and healthcare executives as we all learn together to navigate the COVID-19 pandemic. Approaching the topic from a variety of angles (providers, digital health messaging, and EHR communications), the panel will provide a valuable opportunity for participants to learn and engage with industry leaders in this discussion about designing solutions to combat the coronavirus.

Date: Thursday, March 26

Time: 1:00 p.m. ET

The webinar is free and open to anyone in the industry and will provide an opportunity to communicate directly with the panelists. OptimizeRx continues to host a series of crucial conversations connecting various healthcare stakeholders to drive innovation, collaboration and education. 

Register today at .

For more information about OptimizeRx’s webinar sessions, contact media relations at (754) 245-7070 or .

About OptimizeRx

OptimizeRx® (NASDAQ: OPRX), a digital health company, connects pharmaceutical companies to patients and providers, offering greater affordability, adherence and brand awareness at the point-of-care. As the nation’s largest digital platform connecting life sciences to the point-of-care, OptimizeRx provides a direct channel for pharma companies, payers, medtech, and medical associations to communicate with healthcare providers right within their workflow and also directly to patients.

The cloud-based solution supports patient adherence to medications and better healthcare outcomes with real-time access to financial assistance, prior authorization, education and critical clinical information. OptimizeRx provides more than half of the ambulatory patient market with access to these benefits through leading EHR platforms like Allscripts, Amazing Charts and Quest, and directly via its mobile communications platform and digital therapeutics SaaS platform.

For more information, follow the company on , or visit .

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

OptimizeRx Contact

Doug Baker, CFO

Tel (248) 651-6568 x807

Media Relations Contact

Maira Alejandra, Media Relations Manager

Tel (754) 245-7070

Investor Relations Contact

Ron Both, CMA

Tel (949) 432-7557

EN
25/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, a...

OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, follow...

 PRESS RELEASE

OptimizeRx Corporation Announces Plan for Additional Board of Director...

OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx’s ongoing process to refresh and expand its board of directors (the “Board”), it intends to appoint a new independent director to its Board of Directors during the second half of this year.  With the appointment of a new independent ...

 PRESS RELEASE

OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial ...

OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended...

 PRESS RELEASE

OptimizeRx Corporation Confirms Receipt of Notice of Director Nominati...

OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations No Stockholder Action Required at this Time WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company’s ...

 PRESS RELEASE

OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive O...

OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company’s new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to Optimiz...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch